Search Within

Hematologic Malignancies, Division of

  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (1072)
  2. Meeting Abstract (1012)
  3. Review (54)
  4. Book Section (40)
  5. Editorial (34)
  6. Research Letter (20)
  7. Guidelines (11)
  8. Conference Paper (7)
  9. Correspondence (5)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2260)
  2. Solid Tumor Oncology Division (2260)
  3. GSK Faculty (946)
  4. Center for Hematologic Malignancies (700)
  5. Genitourinary Oncology Service (649)
  6. Epidemiology and Biostatistics (632)

More Groups

People
  1. Roisin O'Cearbhaill (268)
  2. Susan Slovin (253)
  3. Sandra D'Angelo (251)
  4. Alexander Shoushtari (244)
  5. Geoffrey Ku (229)
  6. Howard Scher (206)

More People

Years
  1. 2025 (55)
  2. 2024 (170)
  3. 2023 (205)
  4. 2022 (224)
  5. 2021 (183)
  6. 2020 (212)

More Years

Publications
  1. Journal of Clinical Oncology (541)
  2. Blood (112)
  3. Annals of Oncology (97)
  4. Clinical Cancer Research (97)
  5. Gynecologic Oncology (94)
  6. Journal for ImmunoTherapy of Cancer (75)

More Publications

Publishers
  1. American Society of Clinical Oncology (568)
  2. Elsevier Inc. (280)
  3. American Association for Cancer Research (234)
  4. Oxford University Press (126)
  5. Nature Publishing Group (120)
  6. American Society of Hematology (117)

More Publishers

Results (2260)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
    Meeting Abstract

    Elimova, E.; Ajani, J. A.; Burris, H. A.; Denlinger, C. S.; Iqbal, S.; Kang, Y. K.; Kim, J. H.; Lee, K. W.; Lin, B.; Mehta, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Murray, J. C.; Huang, Q.; Hu, C.; Curran, E.; Wong, C.; Glatz, L.; Wang, T.; Hasan, A.; Villaruz, L.; Schoenfeld, A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
    Meeting Abstract

    Betof Warner, A.; Smithy, J. W.; Los, C.; Kalvin, H.; Hasson, N.; Amaria, R. N.; Andrade Czapla, J. A.; Schollenberger, M.; furness, A.; Hassel, J. C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
    Meeting Abstract

    Lebbe, C.; Nghiem, P.; Bhatia, S.; Mortier, L.; Brohl, A. S.; Jacob, N.; Tyroller, K.; Hoffman, J.; D'Angelo, S. P.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
    Meeting Abstract

    Cohen, J. V.; Garyantes, T. K.; Muller, C.; Natale, C. A.; Orloff, M.; Patel, S.; Rodon, J.; Shoushtari, A. N.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
    Meeting Abstract

    Klempner, S. J.; Shen, L.; Liu, D.; Dayyani, F.; Kratz, J.; Pan, H.; Liang, X.; Wang, Z.; Kim, S.; Deng, Y.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity
    Meeting Abstract

    Thorball, C. W.; Quandt, Z.; Saha, A.; Yao, L.; Midda, P.; Xu, Y.; Bejan, C. A.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers
    Meeting Abstract

    Sacco, J. J.; Carvajal, R. D.; Hamid, O.; Kirk, P. B.; Collins, L.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A. P.; Hernandez-Aya, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
    Meeting Abstract

    González-Martín, A.; Pothuri, B.; Ginesta, M. P. B.; Graybill, W. S.; Vergote, I. B.; McCormick, C.; Mirza, M. R.; Moore, R. G.; Lorusso, D.; O'Cearbhaill, R. E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors
    Meeting Abstract

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood (2024)

    Fulltext@MSK | Save